Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study

Norah L. Crossnohere, Ryan Fischer, Andrew Lloyd, Lisa A. Prosser and John F. P. Bridges
Additional contact information
Norah L. Crossnohere: Department of Biomedical Informatics, Ohio State University Wexner Medical Center, Columbus, OH
Ryan Fischer: Parent Project Muscular Dystrophy, Hackensack, NJ, USA
Andrew Lloyd: Acaster Lloyd Consulting Ltd, London, UK
Lisa A. Prosser: University of Michigan Medical School, Ann Arbor, MI, USA
John F. P. Bridges: Department of Biomedical Informatics, Ohio State University Wexner Medical Center, Columbus, OH

Medical Decision Making, 2021, vol. 41, issue 2, 209-221

Abstract: Background Duchenne muscular dystrophy is a rare degenerative neuromuscular disorder with pediatric onset. Recent approvals in Duchenne have placed attention on the economic evaluation in pricing and reimbursement decisions across a range of rare conditions. We sought to assess the appropriateness of the EQ-5D, a common measure of generic health state utility, for use among patients and caregivers affected by Duchenne. Methods An international, cross-sectional sample of adults with Duchenne and caregivers reported patient health status using self- or proxy-reported EQ-5D-3L. Appropriateness was assessed across 6 domains of concern raised by stakeholders in Duchenne. These concerns were that the EQ-5D/EQ-VAS would not capture meaningful differences in health status, correlate with disease-specific measures, reflect real health status, exhibit face validity, be accurately interpreted, and be low burden. We evaluated these concerns by comparing EQ-5D index score and EQ-VAS scores to other condition-specific functional measures and open- and closed-ended questions. Results In total, 263 participants (74% response) completed the survey, 24% of whom were adult patients. Most participants lived in the United States or United Kingdom (58%). Patient age ranged from 1 to 48 y. EQ-5D index was higher in ambulatory than nonambulatory patients (0.60 v. 0.30, P

Keywords: cost utility analysis; health technology assessment; quality of life; rare diseases; utilities (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X20978390 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:41:y:2021:i:2:p:209-221

DOI: 10.1177/0272989X20978390

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().